Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine

Author(s): Mohamed Altai, Anna Orlova, Vladimir Tolmachev

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 14 , 2014

Become EABM
Become Reviewer
Call for Editor


Receptor tyrosine kinases (RTK) are transmembrane receptors regulating cellular proliferation, differentiation, apoptosis, motility and recruitment of the vasculature. Aberrant expression and/or function of RTK have been detected in many malignant tumors and are considered to be a part of the transformed phenotype. The action of several classes of anti-cancer drugs is based on specific recognition of RTK. Monoclonal antibodies target extracellular binding domains, while tyrosine kinase inhibitors (TKI) bind to intracellular kinase domains to suppress RTK signaling. The issues regarding the efficient use of RTK targeting are the inter- and intra-patient heterogeneity of RTK expression and the changes of expression levels during the course of disease and in response to therapy. Radionuclide molecular imaging of RTK expression may aid in selecting patients who would benefit from RTK-targeting therapy and in identifying non-responders. Therefore, the therapy would be more personalized. Currently, radiolabeled proteins (monoclonal antibodies and their fragments, natural peptides ligands to RTK and de novo selected affinity proteins) and TKI and their analogues are under development for the visualization of RTK. In this review, we discuss the advantages and disadvantages of these approaches.

Keywords: Radionuclide, molecular imaging, receptor tyrosine kinases, monoclonal antibodies, tyrosine kinase inhibitors, scaffold proteins.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 11 September, 2013
Page: [2275 - 2292]
Pages: 18
DOI: 10.2174/13816128113196660667
Price: $65

Article Metrics

PDF: 34